New York, January 5, 2026, 13:03 EST — Regular session
Abivax (ABVX) shares fell about 9.1% to $121.64 in midday U.S. trading on Monday, after touching $133.73 earlier in the session. The stock hit a low of $121.08, while its Paris-listed shares ended down 9.7%.
The pullback matters because Abivax has turned into a high-beta biotech name, where sentiment swings can be abrupt and outsized. Investors have been weighing a rich valuation built on late-stage trial hopes and deal chatter, and Monday’s drop tested how much of that optimism is still in the price.
The move came as biotech broadly slipped, with the SPDR S&P Biotech ETF (XBI) down about 2.1% and the iShares Nasdaq Biotechnology ETF (IBB) down about 1.7%. Traders are also looking ahead to the J.P. Morgan Healthcare Conference in San Francisco on Jan. 12-15, a traditional focal point for sector outlooks and deal talk.
Abivax trades in the U.S. via American depositary shares, or ADSs — receipts that let investors buy foreign shares on a U.S. exchange. ADS listings can amplify volatility when momentum-driven flows dominate a small float.
The French biotech is developing obefazimod for ulcerative colitis, a chronic inflammatory bowel disease that can cause abdominal pain and persistent diarrhea. A July 2025 SEC filing said Abivax’s ongoing Phase 3 maintenance trial — a longer-term study meant to test durability after initial treatment — is expected to deliver top-line results in the second quarter of 2026.
Abivax has also been lining up scientific visibility ahead of 2026 readouts. “We are highly enthusiastic about the strong presence of obefazimod data at the 21st ECCO Congress,” Chief Executive Marc de Garidel said in a Dec. 17 release on planned presentations at the European Crohn’s and Colitis Organization meeting in Stockholm, including an oral session on Feb. 21.
Deal speculation has added another layer of sensitivity. Reuters reported in December that Abivax shares had jumped on a report about possible interest from Eli Lilly, underscoring how takeover chatter can move the stock even without new clinical data.
Still, the fundamental risk remains clinical and financial. Abivax is pre-commercial and continues to spend heavily on development; the company said in mid-December it had cash and cash equivalents of 589.7 million euros and a cash runway into the fourth quarter of 2027, alongside a widening net loss for the first nine months of 2025.
From a trading perspective, Monday’s slide pushed the shares back toward their session low after opening near the prior close, a pattern that often draws short-term sellers. A bounce would need steadier risk appetite across biotech, while a break to fresh lows would put the next support zones in play.
